Meta AnalysisID 6718
补肺活血胶囊治疗尘肺病的疗效与安全性：一项系统评价与Meta分析
CRD42023494441
Pneumoconiosis is accepted as one of the most lethal occupational diseases. For decades, the World Health Organization (WHO) and International Work Organization (ILO) have been focused on eliminating pneumoconiosis globa
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6718
- Evidence Id
- 15276
- Core Evidence Id
- 15276
- Source Meta Analysis Id
- 6701
- Herb2 Meta Analysis Id
- HBMA006701
- Crd Id
- CRD42023494441
- Title
- Efficacy and safety of Bufei Huoxue Capsule in the treatment of pneumoconiosis: a systematic review and meta-analysis.
- Review Question
- Pneumoconiosis is accepted as one of the most lethal occupational diseases. For decades, the World Health Organization (WHO) and International Work Organization (ILO) have been focused on eliminating pneumoconiosis globally. To date, pneumoconiosis is incurable. Novel approaches to effective treatment are urgently needed. In recent years, natural drugs or Chinese herb extracts in pneumoconiosis treatment has been steadily acknowledged. It is reported that Traditional Chinese Medicine (TCM) has a good therapeutic effect on pneumoconiosis, which can improve quality of life, respiratory function, and oxidative stress. Bufei Huoxue Capsule is composed of Astragalus membranaceus, red peony, and Psoralea corylifolia. It is clinically suitable for the supplementary treatment of pneumoconiosis. This study was aimed to systematically assemble the evidence of pneumoconiosis treatment with Bufei Huoxue Capsules to provide reference for clinicians
- Study Type Included
- All published RCTs for patients with pneumoconiosis by BFHXC were included. The exclusion criteria were: (1) Non-RCTs including conference reports, review literature, animal tests, and theoretical experience; (2) incomplete data and duplicated data; (3) experimental group treated with other Chinese medicines.
- Condition Being Studied
- Pneumoconiosis is a collection of various occupational lung diseases caused by inhalation of airborne dust and fibers. Exposures to asbestos, silica, and coal dust are well acknowledged risk factors for pneumoconiosis. Among the current occupational diseases in China, there are 12 kinds of statutory pneumoconiosis, which can all eventually induce irreversible lung damage and has the potential to cause progressive physical disabilities. At present, large number of industrial applications and working activities involving the use or handling of silica containing materials, an estimated number of millions of workers are exposed to harmful dust worldwide.
- Participant
- All published RCTs for patients with pneumoconiosis by BFHXC were included, without limitations of gender, race, and age. The diagnosis of pneumoconiosis should conform to the national diagnostic standard of pneumoconiosis or its previous version (GBZ 70-2002/GBZ 70-2009), regardless of the specific classification and stage of illness.
- Animal
- Human Disease Modelled
- Intervention
- The treatment group of pneumoconiosis patients was treated with Bufei Huoxue Capsule.
- Comparator Control
- Patients use conventional treatment, which includes oxygen therapy, Western Medicine such as ICS, LAMA, LABA, and expectorant drug, antispasmodic drugs and placebo granule.
- Main Outcome
- The outcome measures included functional capacity, and dyspnea score, such as modified Medical Research Council (mMRC) dyspnea scale and chronic obstructive pulmonary disease (COPD) Assessment Test（CAT）.
- Outcome Measure
- Additional Outcome
- 1. Partial pressure of oxygen and carbon dioxide in arterial blood. 2. Immunity-related Indexes in blood. 3. Quality of life evaluation, such as St. George's Respiratory Questionnaire (SGRQ). 4. 6-minute walking distance (6MWD). 5. Clinical efficacy, etc.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Hang Wenlu [email protected]
- Organisational Affiliation
- None None
- Funding Source
- Jiangsu Natural Science Foundation Youth Program (No. BK20220236),
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-12-17
- Registration Date
- 2023-12-28
- Anticipated Start Date
- 2023-12-18
- Anticipated Completion Date
- 2024-01-31
- Title Cn
- 补肺活血胶囊治疗尘肺病的疗效与安全性：一项系统评价与Meta分析
- Title En
- Efficacy and safety of Bufei Huoxue Capsule in the treatment of pneumoconiosis: a systematic review and meta-analysis.
- Bilingual Status
- complete